{"slideshow_credits": null, "snippet": "The Leukemia and Lymphoma Society notes the major regulatory challenges ahead.", "abstract": null, "section_name": "Opinion", "print_page": "28", "document_type": "article", "byline": [], "web_url": "http://www.nytimes.com/2012/12/17/opinion/new-cancer-treatments.html", "lead_paragraph": "The Leukemia and Lymphoma Society notes the major regulatory challenges ahead.", "headline": {"main": "New Cancer Treatments", "print_headline": "New Cancer Treatments", "content_kicker": "Letter", "kicker": "Letter"}, "_id": "50d0e52b00315214fbb7fbe8", "word_count": "178", "multimedia": [], "pub_date": "2012-12-17T00:00:00Z", "source": "The New York Times", "news_desk": "Letters", "keywords": [{"value": "Leukemia", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Regulation and Deregulation of Industry", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Cancer", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "Letter"}